

Progress, at What Price?



CANCER
PROGRESS
by Defined Health

Progress, at What Price?

Moderator:

Ed Saltzman, President, Defined Health

Panelists:

- *Peter Bach, MD*, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- *Michael Kolodziej, MD*, National Medical Director, Oncology Solutions, Aetna
- *Lee Newcomer, MD, MHA*, SVP, Oncology, Genetics and Women's Health, United Healthcare
- *Leonard Saltz, MD*, Professor of Medicine, Weill Cornell Medical College; Chief, Gastrointestinal Oncology Service, Chair, Pharmacy and Therapeutics Committee, Memorial Sloan Kettering Cancer Center

March 2014- March 2015 Oncology Approvals

Drug	Company	Approval Date	Cost (\$)/Month
Blinatumomab (Blincyto)	Amgen Inc.	3-Dec-14	71,200
Belinostat (Beleodaq)	Spectrum Pharmaceuticals, Inc.	3-Jul-14	35,000
Lenvatinib (Lenvima)	Eisai	13-Feb-15	15,624
Ramucirumab (Cyramza)	Eli Lilly & Co.	21-Apr-14	13,382
Ceritinib (Zykadia)	Novartis	29-Apr-14	12,598
Nivolumab (Opdivo)	Bristol-Myers Squibb Company	22-Dec-14	11,798
Olaparib (Lynparza)	AstraZeneca	19-Dec-14	11,200
Panobinostat (Farydak)	Novartis	23-Feb-15	10,976
Siltuximab (Sylvant Injection)	Janssen Biotech, Inc.	23-Apr-14	10,018
Palbociclib (Ibrance)	Pfizer, Inc.	3-Feb-15	9,850
Pembrolizumab (Keytruda)	Merck Sharp & Dohme Corp	4-Sep-14	9,438
Idelalisib (Zydelig tablets)	GileadSciences, Inc.	23-Jul-14	7,385
filgrastim-sndz (Zarxio Injection) Biosimilar	Sandoz Inc.	6-Mar-15	N/A
Dinutuximab (Unituxin)	United Therapeutics Corporation	10-Mar-15	N/A

March 2014- March 2015 Oncology Approvals

Drug	Company	Approval Date	Cost (\$)/Month
Ramucirumab (Cyramza)	Eli Lilly & Co.	21-Apr-14	13,382
Siltuximab (Sylvant Injection)	Janssen Biotech, Inc.	23-Apr-14	10,018
Ceritinib (Zykadia)	Novartis	29-Apr-14	12,598
Belinostat (Beleodaq)	Spectrum Pharmaceuticals, Inc.	3-Jul-14	35,000
Idelalisib (Zydelig tablets)	GileadSciences, Inc.	23-Jul-14	7,385
Pembrolizumab (Keytruda)	Merck Sharp & Dohme Corp	4-Sep-14	9,438
Blinatumomab (Blincyto)	Amgen Inc.	3-Dec-14	71,200
Olaparib (Lynparza)	AstraZeneca	19-Dec-14	11,200
Nivolumab (Opdivo)	Bristol-Myers Squibb Company	22-Dec-14	11,798
Palbociclib (Ibrance)	Pfizer, Inc.	3-Feb-15	9,850
Lenvatinib (Lenvima)	Eisai	13-Feb-15	15,624
Panobinostat (Farydak)	Novartis	23-Feb-15	10,976
filgrastim-sndz (Zarxio Injection) Biosimilar	Sandoz Inc.	6-Mar-15	N/A
Dinutuximab (Unituxin)	United Therapeutics Corporation	10-Mar-15	N/A

Progress, at What Price?

Moderator:

Ed Saltzman, President, Defined Health

Panelists:

- *Peter Bach, MD*, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- *Michael Kolodziej, MD*, National Medical Director, Oncology Solutions, Aetna
- *Lee Newcomer, MD, MHA*, SVP, Oncology, Genetics and Women's Health, United Healthcare
- *Leonard Saltz, MD*, Professor of Medicine, Weill Cornell Medical College; Chief, Gastrointestinal Oncology Service, Chair, Pharmacy and Therapeutics Committee, Memorial Sloan Kettering Cancer Center